1	Acute pharmacodynamic responses to exenatide:
2	Drug-induced increases in insulin secretion and glucose effectiveness
3	
4	Simeon I. Taylor MD, PhD ¹ May E. Montasser PhD ¹ Ashley H. Yuen MD ¹
5	Hubert Fan ² Zhinoosossadat Shahidzadeh Yazdi MD ¹ Hilary B. Whitlatch MD ¹
6	Braxton D. Mitchell PhD, MPH ¹ Alan R. Shuldiner MD ¹ Ranganath Muniyappa MD PhD ²
7	Elizabeth A. Streeten MD ¹ Amber L. Beitelshees PharmD, MPH ¹
8	
9	¹ Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of
10	Maryland School of Medicine, Baltimore, MD 21201, USA
11	² Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and
12	Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
13	
14	Correspondence
15	Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,
16	Baltimore, MD 21201, USA
17	Email: <u>staylor2@som.umaryland.edu</u>
18	Funding information: American Diabetes Association (1-16-ICTS-112) and National Institute of
19	Diabetes and Digestive and Kidney Disease (R01DK130238, T32DK098107, and
20	P30DK072488)
21	Trial registration: NCT05762744 (clinicaltrials.gov)
22	Study review and approval: Institutional Review Board of the University of Maryland Baltimore
23	

24 ABSTRACT

25 Background: GLP1R agonists provide multiple benefits to patients with type 2 diabetes – 26 including improved glycemic control, weight loss, and decreased risk of major adverse 27 cardiovascular events. Because drug responses vary among individuals, we initiated 28 investigations to identify genetic variants associated with the magnitude of drug responses. 29 **Methods**: Exenatide (5 µg, sc) or saline (0.2 mL, sc) was administered to 62 healthy volunteers. Frequently sampled intravenous glucose tolerance tests were conducted to assess the impact 30 31 of exenatide on insulin secretion and insulin action. This pilot study was designed as a 32 crossover study in which participants received exenatide and saline in random order. 33 **Results**: Exenatide increased first phase insulin secretion 1.9-fold (p=1.9x10⁻⁹) and accelerated the rate of glucose disappearance 2.4-fold ($p=2x10^{-10}$). Minimal model analysis demonstrated 34 that exenatide increased glucose effectiveness (S_{α}) by 32% (p=0.0008) but did not significantly 35 affect insulin sensitivity (S_i). The exenatide-induced increase in insulin secretion made the 36 37 largest contribution to inter-individual variation in exenatide-induced acceleration of glucose disappearance while inter-individual variation in the drug effect on S_a contributed to a lesser 38 extent (β =0.58 or 0.27, respectively). 39 40 **Conclusions:** This pilot study provides validation for the value of an FSIGT (including minimal 41 model analysis) to provide primary data for our ongoing pharmacogenomic study of pharmacodynamic effects of semaglutide (NCT05071898). Three endpoints provide quantitative 42 assessments of GLP1R agonists' effects on glucose metabolism: first phase insulin secretion, 43 glucose disappearance rates, and glucose effectiveness. 44

45

46 **Registration**: NCT02462421 (clinicaltrials.gov)

47 **Funding**: American Diabetes Association (1-16-ICTS-112); National Institute of Diabetes and

48 Digestive and Kidney Disease (R01DK130238, T32DK098107, P30DK072488)

49 1 | Introduction

Head-to-head comparative effectiveness studies demonstrate that diabetes drugs are not 50 strongly differentiated with respect to their effectiveness to decrease mean HbA1c¹. 51 52 Nevertheless, individual patients vary widely in their responses to individual therapies. For 53 example, semaglutide (1.0 mg/wk) decreased HbA1c by an average of 1.64% (SEM \approx 0.05%; SD \approx 0.95%) in patients with baseline HbA1c=8.17%². The observed magnitude of standard 54 55 deviation suggests that some patients experienced little if any decrease in HbA1c while others experienced >2.5% HbA1c-lowering. This inter-individual variation may result from genetics. 56 57 environment, or interplay between both factors. Pharmacogenetics has potential to guide treatment decisions, enabling clinicians to recommend optimal therapy for individual patients 58 based on individualized predictors of responsiveness and susceptibility to adverse effects ¹. 59 Pharmacogenomic studies have identified genetic variants associated with the magnitude of 60 61 responses to several diabetes drugs, including metformin, sulfonylureas, and GLP1 receptor agonists ³⁻⁷. While some genetic variants alter a drug's pharmacokinetics, other genetic variants 62 63 alter pharmacodynamics by altering functions of proteins that mediate drug responses. Although 64 genetic variation in pharmacokinetics may be less relevant for responses to an injectable peptide drug such as exenatide, genetic variants in the GLP1R gene have been reported to be 65 associated with pharmacodynamic responses to GLP1 receptor agonists ⁴⁻⁷. 66

We initiated this clinical trial as a pilot and feasibility study for our ongoing genome-wide association study of responses to semaglutide (NCT05071898). Specifically, we conducted frequently sampled intravenous glucose tolerance tests (FSIGT) to assess pharmacodynamic responses to a rapid-acting GLP1R agonist (exenatide): glucose-stimulated insulin secretion and the rate of glucose disappearance. We applied the "minimal model" to analyze FSIGT data. This mathematical model describes the time course for plasma glucose levels to return to

73 baseline after an intravenous glucose challenge as a function of the time course of glucose-74 stimulated insulin secretion and two parameters: insulin sensitivity (S_i) and glucose effectiveness (S_{α})⁸. S_{α} reflects insulin-independent mechanisms whereby plasma glucose 75 76 concentration drives the return of plasma glucose to baseline levels during an FSIGT. Herein we 77 summarize pharmacodynamic responses to exenatide in the overall study population as well as 78 in sub-groups who were homozygous for two genetic variants, GIPR (p.E354Q; rs1800437) and GCGR (p.G40S; rs850763). The choice of these two candidate genes was inspired by intriguing 79 observations suggesting interactions among GLP1, GIP, and glucagon ⁹. Specifically, peptide 80 drugs that target multiple receptors (GLP1R, GIPR, and GCGR) are reported to exert stronger 81 pharmacological effects than selective drugs targeting only one receptor ⁹. Just as exogenous 82 administration of agonists targeting GIPR and GCGR enhance pharmacological responses to an 83 exogenous GLP1R agonist, we hypothesized that response to an exogenous GLP1R agonist 84 85 might be modulated by effects of endogenous agonists mediated by GIPR and/or GCGR. We focused on two variants (rs1800437 and rs850763), which have been reported to alter the 86 function of GIPR and GCGR, respectively ^{10,11}. 87

89 2 | Methods

90 2.1 | Study population: recruitment and screening

91 The Old Order Amish population of Lancaster County, PA emigrated from Central Europe in the 92 early 1700's. University of Maryland School of Medicine researchers have been studying 93 genetic determinants of cardiometabolic health in this population since 1993. To date, ~10.000 94 Amish adults participated in one or more studies as part of the Amish Complex Disease 95 Research Program (http://www.medschool.umaryland.edu/endocrinology/Amish-Research-Program/). These studies generated a genotype database that was used to identify individuals 96 with any of three genotypes who were eligible for our clinical trial: (a) homozygotes for a 97 missense variant in GIPR (p.E354Q; rs1800437); (b) homozygotes for a missense variant in 98 99 GCGR (p.G40S; rs850763); and (c) individuals who were homozygous for the "wild type" major 100 alleles of GIPR and GCGR. A research nurse, accompanied by a member of the Amish community, made home visits to invite individuals to participate in the study. If they expressed 101 102 interest, the study was explained in detail; potential participants were invited to sign an informed 103 consent form. Thereafter, the research nurse obtained a medical history; measured height, 104 weight and blood pressure; and obtained blood samples for screening laboratory tests (hematocrit, fasting plasma glucose, serum creatinine, serum AST, serum ALT, plasma TSH, 105 106 and HbA1c).

107 2.2 | Study design: overview

The study was designed as a crossover study in which healthy individuals were randomized between administration of exenatide (5 µg, sc) or saline (0.2 mL, sc). Fifteen minutes after the injections, participants underwent a frequently sampled intravenous glucose tolerance test (FSIGT) as described in the Supplementary Appendix. A second FSIGT was conducted 5-28 days later; each participant received the treatment (either saline or exenatide) not administered

for the first FSIGT. All procedures were reviewed and approved by the University of MarylandBaltimore IRB.

- 115 Practical considerations guided our selection of exenatide as the GLP1R agonist for this pilot
- study. Exenatide is rapidly absorbed and could be administered 15 min prior to initiation of the
- 117 FSIGT. In contrast, liraglutide (the principal alternative in 2015 when this study was initiated)
- achieves Cmax ~10-12 hours after injection ¹². The logistics of administering an injection 10-12
- 119 hours prior to the FSIGT would have been challenging in this out-patient study.
- 120 2.3 | Power calculations
- 121 We aimed to recruit 24 research participants for each of the three genotypes. We estimated that

these recruitment targets provided 80% power (with p=0.05) to detect association with a 35%

123 change in first-phase insulin secretion and a 25% change in glucose disappearance rate for

124 homozygous variant compared to homozygous wild-type individuals. However, the clinical trial

125 was terminated early when it became apparent that we would not meet our recruitment targets

126 within the available budget.

127 2.4 | Eligibility criteria

To be eligible to participate in the clinical trial, individuals were required to be of Amish descent, at least 18 years old, and have BMI between 18-40 kg/m². Exclusion criteria are summarized in the Supplementary Appendix.

131 2.5 | Clinical chemistry

- Processing of blood samples and laboratory methods are summarized in the SupplementaryAppendix.
- 134 2.6 | Data and statistical analyses

135 We established two primary end points: drug effects on (a) first phase insulin secretion and (b) 136 glucose disappearance rate. Fig. 1 presents untransformed data on plasma levels of insulin and glucose. Tables 1 and 2 present analyses of logarithmic transformation of data on AIR_q, S_i, S_q, 137 and glucose disappearance rates because the untransformed data were not normally 138 139 distributed. Data in all the other Figures and Tables were inverse normally transformed and 140 multiplied by SD to have effect size in real units; all analyses in those Figures and Tables were 141 adjusted for age, sex, and BMI. Genetic association analysis (Table S3) was performed using 142 linear mixed models to account for familial correlation using the kinship relationship matrix as 143 implemented in the Mixed Model Analysis for Pedigree and population [https://mmap.github.io/]. Multiple regression analysis was conducted using Excel. Minimal model analyses were 144 conducted as described elsewhere ¹³⁻¹⁵. Minimal model analysis of the FSIGT data was used to 145 estimate indices of glucose effectiveness (S_{α}) and insulin sensitivity (S_i) as previously described 146 147 using MINMOD software (version 6.02) (MinMOD Millenium, Los Angeles, CA) ¹⁵. AIR_d is 148 calculated as the area under the curve for first phase insulin secretion between 0-10 minutes. Disposition Index was calculated as the product of S_i multiplied by AIR_a⁸. 149 150 Statistical significance was assessed using a paired t-test. Although a p-value of p<0.05 was 151 defined as the threshold for nominal statistical significance, a more stringent threshold (e.g.,

152 p<0.001) may be appropriate to account for multiple comparisons.

153 3 | Results

154 3.1 | Disposition and adverse events

Research participants' baseline characteristics are summarized in Table S1. Disposition of
participants and adverse events are summarized in Fig. S1. Seventy-eight individuals were
enrolled in this clinical trial between June, 2016 - November, 2018. Sixty-two participants
completed frequently sampled intravenous glucose tolerance tests.
3.2 | Intravenous glucose tolerance tests: impact of exenatide

Intravenous administration of glucose triggered prompt increases in plasma levels of glucose 160 and insulin (Fig. 1). Plasma glucose achieved a peak at ~4 min – after which time glucose levels 161 decreased. Administration of exenatide augmented insulin secretion. We defined indices to 162 163 guantitate exenatide's direct effect on glucose-stimulated insulin secretion and exenatide's 164 indirect effect on the rate of glucose disappearance (Table S2). As illustrated by the time course of insulin levels in exenatide-treated individuals (Fig. 1), insulin secretion was biphasic. 165 Consistent with published literature ^{12,16}, the area-under-the-curve (AUC) between 0-10 min 166 167 provides an index of first phase insulin secretion (Table S2). We used AUC between 10-50 min 168 as an index of second phase insulin secretion. The higher plasma insulin levels observed in exenatide-treated individuals accelerated the rate at which glucose levels declined. During the 169 time interval between 25-50 min, the plot of log(glucose) versus time approximates a straight 170 line. The slope of that line served as index of the rate of glucose disappearance (Table S2)¹². 171 Exenatide triggered statistically significant increases in the areas under the curve (AUCs) for 172 first phase (~1.9-fold; p=1.9x10⁻⁹; Fig. S2) and second phase (~3.5-fold; p=1x10⁻⁹) insulin 173 secretion as well as the rate of glucose disappearance (~2.4-fold; $p=2x10^{-10}$; Fig. S2). Values for 174 first phase and second phase insulin secretion were closely correlated (r=0.74, p=2.4x10⁻¹⁰ for 175 placebo data; r=0.63, $p=3.4\times10^{-7}$ for data after administration of exenatide) (Fig. S3). 176

177 Because curves describing time courses for mean glucose levels in the placebo and exenatide 178 studies are essentially superimposable during the first ten minutes (Fig. 1), the drug effect on first phase insulin secretion likely represents a direct effect of exenatide. In contrast, exenatide's 179 effect on second phase insulin secretion (10-50 min) likely reflects a balance between 180 181 exenatide's positive direct effect on insulin secretion and the negative impact of lower glucose 182 levels tending to decrease insulin secretion. Accordingly, we emphasized first phase insulin secretion to assess the correlation between insulin secretion and the rate of glucose 183 disappearance. The rate of glucose disappearance (as defined in Table S2) was correlated with 184 first phase insulin secretion (r=0.74, p=2.4 x 10⁻¹⁰ for placebo data; r=0.63, 3.4x10⁻⁷ for data 185 after administration of exenatide) (Fig. 2AB). As illustrated in the histograms (Fig. S4), we 186 observed substantial inter-individual variation in indices for drug effects on both stimulation of 187 188 insulin secretion and acceleration of glucose disappearance. While exenatide exerted little or no 189 effect in some individuals, greater than 5-fold increases were observed in other individuals. 3.2 | Intravenous glucose tolerance tests: exenatide increases glucose effectiveness 190 191 Exenatide's effect on the rate of glucose disappearance was correlated with the magnitude of 192 exenatide's effect on insulin secretion (r=0.70; $p=9.2x10^{-9}$) (Fig. 2C). The correlation coefficient 193 suggests that inter-individual variation in the magnitude of exenatide's direct effect on insulin 194 secretion explains approximately half of the observed variance in the magnitude of exenatide's 195 indirect effect on the rate of glucose disappearance. Accordingly, we searched for other factors 196 that might have contributed to variation in the effect of exenatide to accelerate glucose disappearance. We applied Bergman's minimal model ^{8,15,17,18} to estimate insulin sensitivity (S_i), 197 198 glucose effectiveness (S_q), and disposition index (DI) (Table 1). Although acute administration of exenatide did not alter insulin sensitivity (p=0.36), exenatide treatment increased glucose 199 200 effectiveness by 32% (p=0.0008), acute insulin response to glucose by 94% ($p=2.3 \times 10^{-10}$) and 201 disposition index by 95% ($p=2.0x10^{-6}$). The rate of glucose disappearance was significantly

202 correlated with glucose effectiveness for data from both placebo studies (r=0.50, p=0.0001; Fig. 3) and exenatide studies (r=0.66, p= 5.4×10^{-8} ; Fig. 3). We conducted multiple regression 203 analyses to further investigate inter-relationships among the parameters of the minimal model in 204 the context of acute administration of exenatide. In the placebo state, inter-individual variation in 205 206 in S_i or AIR_g each made similar magnitude contributions to inter-individual variation the rate of 207 glucose disappearance. An increase of 1 standard deviation unit (SDU) in S_i or AIR_d was 208 associated with an increase of ~0.4 SDU in the rate of glucose disappearance (Table 2). Inter-209 individual variation in glucose effectiveness made a smaller contribution (i.e., 0.2 SDU increase 210 in glucose disappearance rates for each SDU increase in S_0 (Table 2). After exenatide 211 administration, variation in all three parameters also contributed, but the effect of variation in 212 AIR_a predominated (an increase of 0.61 SDU in the rate of glucose disappearance per 1 SDU 213 increase in insulin secretion); the impact of variations in insulin sensitivity and glucose 214 effectiveness were smaller (Table 2). Variation in the magnitude of the drug effect on insulin 215 secretion was the principal determinant of the magnitude of the drug effect on the rate of 216 glucose disappearance. An increase of 1 SDU in the drug effect on AIR_q was associated with an increase of 0.58 ± 0.12 SDU in the magnitude of the drug effect for the rate of glucose 217 218 disappearance ($p=7.2 \times 10^{-7}$) (Table 2).

219 3.3 | Effect of genotype

This pilot study was designed to test the hypothesis that missense variants in two candidate genes (*GCGR* and *GIPR*) might be associated with pharmacodynamic responses to GLP1 receptor agonists. Table S3 compares pharmacodynamic responses to exenatide among three groups of people: (a) individuals who are homozygous for the major alleles of both genes; (b) homozygotes for the G40S variant of *GCGR* (rs1801483) ^{11,19}; and (c) homozygotes for the E354Q variant of *GIPR* (rs1800437) ^{10,20,21} (Table S3). Four co-primary endpoints were prespecified: association of genotype (either G40S-*GCGR* or E354Q-*GIPR*) with the magnitude of

- 227 drug effect (i.e., either exenatide-induced augmentation of first phase insulin secretion or
- 228 exenatide-induced acceleration of the rate of glucose disappearance). We did not observe
- statistically significant associations between any of the genetic variants and either of the
- endpoints.
- 231

232 4 | Discussion

Pharmacogenomic research has utilized varied approaches – including acute studies in healthy 233 volunteers assessing acute pharmacodynamic endpoints ^{3,22} and chronic studies in disease 234 patients assessing routine clinical endpoints such as HbA1c²³. Short-term studies in healthy 235 volunteers offer several methodological advantages - for example, minimization of confounding 236 factors caused by co-existing diseases or effects of changing co-medications during the course 237 238 of the study. This pilot study provided an opportunity to validate pharmacodynamic endpoints for 239 our currently ongoing genome-wide association study of the genetics of pharmacodynamic responses to a GLP1 receptor agonist (NCT05071898). As exemplified by the usual stepwise 240 241 approach to drug development, it is informative to conduct pilot studies to validate methods and 242 analytic approaches before initiating a larger clinical trial. Our results confirm the existence of 243 substantial inter-individual variation in pharmacodynamic responses to exenatide – ranging from no significant increase to a 5- to 6-fold increase for glucose-sensitive insulin secretion or 244 acceleration of glucose disappearance, respectively. The wide range of inter-individual variation 245 246 in the magnitude of drug response emphasizes the potential value of identifying genetic variants to predict an individual's pharmacological response and provide guidance to physicians in 247 248 selecting the best diabetes drug for each individual patient.

249 FDA-approved prescribing information for GLP1R agonists identifies several important clinical 250 benefits for this class of drugs: HbA1c-lowering in patients with type 2 diabetes, weight loss in overweight/obese patients, and decreasing major adverse cardiovascular events in patients with 251 type 2 diabetes ²⁴⁻²⁶. Our clinical trial assessed drug-induced acceleration of glucose 252 253 disappearance in healthy non-diabetic individuals, which is mechanistically related to drug-254 induced HbA1c lowering in patients with type 2 diabetes. Mediation analysis of the LEADER 255 cardiovascular outcome trial suggested that ~90% of liraglutide's beneficial impact on cardiovascular risk reduction was mediated by the drug-induced decrease in HbA1c²⁷. This 256

suggests that genetic variants associated with glycemic effects may also contribute to predicting
 the magnitude of cardiovascular risk reduction. Comparative effectiveness confirmed that
 GLP1R agonists providing the largest HbA1c-lowering also provided the greatest
 cardioprotection ^{28,29}.

4.1 | Acute exenatide-induced acceleration of glucose disappearance: mechanisms

262 Exenatide increased the magnitude of the mean glucose-stimulated 1st phase insulin secretion 263 by 1.9-fold, 3.5-fold increase for 2nd phase insulin secretion, and 2.1-fold increase for the glucose disappearance rate (Figs. 1 and S2; Table 1). Furthermore, exenatide caused a 32% 264 265 increase in mean glucose effectiveness (S_q) but did not induce a significant change in mean 266 insulin sensitivity (Table 1). The impact of the exenatide-induced increase in S_g is supported by the observation that rates of glucose disappearance were correlated with the magnitude of S_a in 267 268 both placebo studies and studies conducted after participants received exenatide (Fig. 3). 269 Multiple regression analysis revealed that inter-individual variation in the magnitudes of glucose-270 stimulated insulin secretion and insulin sensitivity appeared to contribute significantly to inter-271 individual variation in the rate of glucose disappearance in both placebo studies and studies 272 conducted after participants received exenatide (Table 2). Thus, although exenatide does not exert an acute effect on insulin sensitivity, pre-existing inter-individual variation in Si does 273 274 contribute significantly to inter-individual variation in rates of glucose disappearance both at 275 baseline and in the exenatide-treated states (Table 2). Notwithstanding smaller contributions from S_g and S_i, inter-individual variation in the magnitude of exenatide-induced increase in 276 glucose-sensitive insulin secretion (AIR_{α}) was quantitatively the most important determinant of 277 278 the magnitude of the drug-induced increase in glucose disappearance (Table 2); a change of 1 279 SDU in the drug effect on AIR $_{a}$ was associated with a 0.58 SDU in the drug effect on the rate of 280 glucose disappearance. These data on effects of exenatide on sub-phenotypes (i.e., insulin 281 secretion and glucose disappearance rate) are generally similar to what has been reported for

liraglutide and lixisenatide ^{12,16} with the exception that lixisenatide was reported not to induce a statistically significant increase in 2^{nd} phase insulin secretion in healthy individuals ¹⁶. Consistent with previous studies of GLP1R agonists ^{12,16,30,31}, we did not detect a significant effect of exenatide on the mean insulin sensitivity index (S_i). The selectivity of the exenatide-induced increase in S_g without affecting S_i supports the conclusion that S_i and S_g reflect distinct aspects of glucose metabolism ⁸.

The term "glucose effectiveness" refers to insulin-independent mechanisms whereby glucose 288 concentrations enhance glucose utilization and/or decrease glucose production⁸. The precise 289 physiological mechanisms mediating glucose effectiveness are not completely understood ⁸. 290 There has been discussion about challenges in estimating glucose effectiveness from data 291 292 derived from intravenous glucose tolerance tests. For example, it has been suggested that 293 higher levels of insulin secretion may lead to higher mathematical estimates of glucose 294 effectiveness; it has been challenging to identify detailed mechanisms accounting for these higher estimates of S_g ^{32,33}. Nevertheless, it is theoretically possible that the exenatide-induced 295 increase in insulin secretion may contribute to the larger mathematical estimates of S_a. Bergman 296 297 ⁸ has suggested that glucose effectiveness may reflect hepatic glucose uptake and metabolism 298 (mediated by GLUT2 and glucokinase). As GLP1 receptor agonists have been reported to 299 suppress glucagon levels ³⁴, this might provide an endocrine mechanism whereby exenatide might exert an indirect effect on hepatic glucose metabolism. However, to the extent that effects 300 301 of exenatide on glucagon secretion by α -cells might be mediated at least in part by paracrine β cell insulin secretion, such an effect would not necessarily be entirely independent of insulin. In 302 303 any case, further research will be required to elucidate physiological mechanisms mediating 304 acute effects of GLP1 receptor agonists on glucose effectiveness.

305 4.2 | Pharmacogenomic candidate genes

306 A missense variant in the GLP1R gene (rs6923761; p.T149M) has previously been reported to 307 be associated with a diminished response to GLP1 receptor agonists ^{6,7,35}. We have not detected this variant in DNA sequences in the Old Order Amish. Recent literature has 308 suggested the existence of positive crosstalk among GLP1, GIP, and glucagon with respect to 309 310 their beneficial effects on insulin secretion and weight loss ³⁶. These considerations led to the design of tirzepatide – a recently approved "twincretin" combining agonist activity against both 311 GLP1R and GIPR ³⁷. Based on these data, we hypothesized that there might be 312 pharmacologically relevant interactions between an exogenous GLP1R agonist and 313 314 endogenous glucagon or GIP. To test these hypotheses, we recruited individuals who are homozygous for two relatively common missense variants: rs1801483 (p.G40S) in GCGR and 315 rs1800437 (p.E354Q) in GIPR. The p.E354Q variant in GIPR has been reported to enhance 316 317 agonist-induced receptor desensitization - potentially leading to resistance to the effect of GIP 318 agonists ¹⁰. Furthermore, this genetic variant in *GIPR* has been reported to be associated with increased plasma levels of GIP as well as various anthropometric and glycemic traits ³⁸. The 319 p.G40S variant in *GCGR* has been reported to impair signaling through β -arrestin-1¹¹. This 320 p.G40S variant in GCGR has been reported to be associated with diabetes ¹⁹ although this 321 finding has not been reproducible ³⁹. 322

323 Although we observed 15-20% numerical decreases in the magnitudes of the effect of 324 exenatide-induced effect on second phase glucose-stimulated insulin secretion in homozygotes 325 for variants in both GIPR (rs1800437) and GCGR (rs1801483), these numerical differences were not statistically significant (Table S3). We encountered greater than expected difficulty in 326 recruiting research participants with genotypes of interest. The small size of the study 327 328 population creates uncertainty about the interpretation of our observations – i.e., whether the 329 statistically insignificant numerical trends toward a decrease in the response to exenatide might represent type II error (incorrect rejection of a false null hypothesis). In order to increase power 330

331 to detect genetic associations, this study focused on homozygotes. Heterozygosity is quite a bit 332 more common and would, therefore, be of greater practical relevance from a pharmacogenomic perspective. Even if one assumes that these variants in GIPR or GCGR are indeed associated 333 334 with responses to GLP1R agonists, we conclude that heterozygosity for these variants is 335 unlikely to exert a large, clinically important effect on responses to GLP1R agonists. Further 336 research will be required to resolve these uncertainties. Whether or not the missense variant in 337 GIPR alters the response to a selective GLP1R agonist, it would be of considerable interest to 338 determine whether the variant in *GIPR* is associated with variation in response to peptides possessing GIPR agonist activity (including tirzepatide) ³⁷. 339

341 ACKNOWLEDGEMENTS

- 342 We gratefully acknowledge funding provided by the American Diabetes Association (grant
- number 1-16-ICTS-112) and National Institute of Diabetes and Digestive and Kidney Disease
- 344 (R01DK130238, T32DK098107, and P30DK072488). We also gratefully acknowledge
- 345 contributions of the research participants and the skilled staff at the Amish Research Clinic for
- their critical roles in making this study possible. We are grateful to Mary Pavlovich, Melanie
- 347 Daue, and Kathy Ryan for their help with database management. Dr. Laura Yerges-Armstrong
- 348 provided genotype data enabling us to identify individuals to be invited to participate in this
- 349 genotype-guided recruitment study.

351 AUTHORS' CONTRIBUTIONS

- 352 Conception of the clinical trial and PI for the grant from the American Diabetes Association grant
- 353 <u>(</u>1-16-ICTS-112<u>)</u>: SIT
- 354 Acquisition and analysis of data: ALB, AHY, MEM, EAS, SIT, HBW, ZSY
- 355 Minimal model analysis of FSIGT data: RM, HF
- 356 Establishment of Old Order Amish genotype database: BDM, ARS
- 357 Preparation of first draft of manuscript: SIT
- 358 Revising and approving final version of manuscript: all authors
- 359 Overall accountability for all aspects of work: SIT

361 Competing Interests

- 362 SIT serves as a consultant for Ionis Pharmaceuticals and receives an inventor's share of
- 363 royalties from NIDDK for metreleptin as a treatment for generalized lipodystrophy. ARS is an
- 364 employee of Regeneron Genetics Center. BDM and MEM receive grant support from
- 365 Regeneron Genetics Center. BDM, MEM, EAS, and HBW have received partial salary support
- 366 from funds provided by RGC. ALB, ZSY, RM, and HF declare no competing interests.

Table 1. Parameters from minimal model analyses. This Table summarizes data from 45

- 368 frequently sampled intravenous glucose tolerance tests conducted after research participants
- 369 received either saline (placebo) or exenatide. Data are presented as means ± SEM. The first
- 370 five rows present analyses of untransformed data whereas the next five rows present analyses
- of logarithmically transformed data. Paired t-tests were conducted on the logarithmically
- transformed data; two-sided p-values are presented in the last column of the Table. Rates of
- 373 glucose disappearance were calculated as described in Table S2. Except for one participant
- 374 with Si of 0.16, the remaining participants' S_i values ranged from 1.4-17.2 x $10^{-4} \cdot \text{min}^{-1} / [\mu U/mL]$
- as compared to a published reference range of 1.4-25.7 x $10^{-4} \cdot \text{min}^{-1}$ / [µU/mL] in lean
- 376 individuals ¹⁸.
- 377
- 378

Parameter	Placebo	Exenatide	p-value
Insulin sensitivity (S _i) ^a	6.80 ± 0.60	7.07 ± 0.58	
Glucose effectiveness (S _g) ^b	0.0139 ± 0.0010	0.0183 ± 0.010	
Acute insulin response (AIR _g) ^c	243 ± 24	472 ± 56	
Disposition index (DI)	1454 ± 157	2833 ± 288	
Glucose disappearance rate ^d	506 ± 31	1060 ± 70	
Log (S _i)	0.73 ± 0.05	0.78 ± 0.04	0.36
Log (S _g)	-1.92 ± 0.04	-1.76 ± 0.03	0.0008
Log (AIR _g)	2.31 ± 0.04	2.58 ± 0.04	2.3 x 10 ⁻¹⁰
Log (DI)	3.04 ± 0.05	3.36 ± 0.04	2.0 x 10 ⁻⁶
Log (glucose disappearance rate)	2.66 ± 0.03	2.96 ± 0.04	1.4x10 ⁻¹³

- 379
- 380 ^a units: $10^{-4} \cdot \text{min}^{-1} / [\mu \text{U/mL}]$
- 381 ^b units: min⁻¹
- 382 ° units: $\mu U \cdot mL^{-1} \cdot min^{-1}$
- 383 ^d units: $10^{-5} \cdot \text{min}^{-1}$

384 Table 2. Relative contributions to the rate of glucose disappearance: beta coefficients from multiple regression of parameters derived from minimal model analysis. The Table 385 386 presents results of multiple regression analyses with three independent variables derived from 387 minimal model analysis of frequently sampled intravenous glucose tolerance tests. The first two columns present data on logarithmically transformed values of insulin sensitivity (S_i), glucose 388 effectiveness (S_{α}), and acute insulin response to glucose (AIR_a) in studies where participants 389 received either saline (placebo) or exenatide. The last column presents analysis of 390 logarithmically transformed data on effects of exenatide (i.e., "drug effects" calculated as 391 392 specified in Table S2) on insulin sensitivity (S_i), glucose effectiveness (S_a), and acute insulin response to glucose (AIR_a). in each analysis, the dependent variable was the rate of glucose 393 disappearance as defined in Table S2. Beta values are expressed in standard deviation units 394 395 (SDU) – i.e., the change in the dependent variable relative to the change in the independent 396 variable in SDU. The last row of the Table presents the overall two-sided p-value for each multiple regression model as calculated using Excel. The footnotes indicate two-sided p-values 397 for each of the coefficients. Units for the minimal model parameters are summarized in Table 1.

398

399 400

Parameter	Placebo	Exenatide	Drug Effect
Insulin sensitivity (S _i)	0.39 ± 0.16^{d}	0.37 ± 0.09°	0.14 ± 0.11 ^e
Glucose effectiveness (S _g)	0.20 ± 0.16 ^{gd}	0.21 ± 0.09 ^f	0.27 ± 0.13 ^g
Acute insulin response (AIR _g)	0.41 ± 0.15°	0.61 ± 0.13 ^b	0.58 ± 0.12 ^a
p-value	0.009	1.9x10 ⁻⁶	5.3x10 ⁻⁸

401

^a p=7.2 x 10⁻⁷; ^b p=0.0004; ^c p=0.01 ^d p=0.02; ^e p=0.03; ^f p=0.15; ^g p=0.23

403 404

.....

405 Figure 1. Exenatide enhances insulin secretion and accelerates the rate of glucose

disappearance decrease in frequently sampled intravenous glucose tolerance tests

- 407 (FSIGT).
- 408 Fifty-three non-diabetic healthy volunteers participated in a randomized crossover study of
- 409 exenatide (N=53). After an overnight fast, participants were randomly assigned to receive either
- 410 exenatide (5 μg, s.c.; solid circles) or saline (0.2 mL, s.c.; open circles). The FSIGT was initiated
- 411 15 min after the s.c. injection by administration of glucose (0.3 g/kg, i.v.) over two minutes.
- Blood samples were obtained for measurement of plasma glucose (panel A) and plasma insulin
- 413 (panel B) over the course of 180 min after glucose administration as described in the Methods
- section ^{8,13,14,17}. After a washout period of 5-28 days, a second FSIGT was conducted in which
- the participant received the treatment (either saline or exenatide) not administered for the first
- 416 FSIGT. Data are presented as means ± SEM.
- 417
- 418
- 419



424 Figure 2. Correlations between the rate of glucose disappearance and first phase insulin

425 secretion. Glucose-stimulated insulin secretion accelerates the rate of glucose disappearance, which in turn provides an "off" signal for insulin secretion. This analysis demonstrates that the 426 427 index for the rate of glucose disappearance between 25-50 min (Table 1) is correlated with the 428 index for first phase insulin secretion (Table 1) in both the placebo-FSIGT (panel A; r=0.74; p=2.4x10⁻¹⁰) and the exenatide-FSIGT (panel B; r=0.63; p=3.4x10⁻⁷). Indices for effects of 429 exenatide on first phase insulin secretion and the rate of glucose disappearance are defined in 430 Table 1. The index for exenatide-induced acceleration of glucose disappearance is correlated 431 with the index for exenatide-induced insulin secretion (panel C; r=0.70; p=9.2x10⁻⁹). Indices for 432 1st phase insulin secretion are expressed as logarithms of AUC expressed in the following units: 433 $[(\mu U/mL) \cdot min]$. Indices for glucose disappearance rates are expressed in the following units: 434 435 $10^{-5} \cdot \text{min}^{-1}$].

- 436
- 437



439 Figure 3. Correlation of rate of glucose disappearance with glucose effectiveness (S_g).

- 440 Rates of glucose disappearance (vertical axis) are plotted as a function of glucose effectiveness
- 441 (S_g) (horizontal axis). The correlation coefficients and p-values are indicated in the Figures for
- the placebo studies (left panel) and the exenatide studies (right panel). Values of S_g are
- 443 expressed in the following units: min⁻¹. Rates of glucose disappearance were calculated as
- summarized in Table S2 expressed in the following units $(10^{-5} \cdot \text{min}^{-1})$.



447 **REFERENCES**

- 1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2
- diabetes: a patient-centered approach: position statement of the American Diabetes
- 450 Association (ADA) and the European Association for the Study of Diabetes (EASD).
- 451 *Diabetes Care.* 2012;35(6):1364-1379.
- 452 2. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and Safety of Once-Weekly
- 453 Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-
- 454 Week, Open-Label, Randomized Clinical Trial. *Diabetes Care.* 2018;41(2):258-266.
- 455 3. Pawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin
- 456 pharmacogenomics: current status and future directions. *Diabetes*. 2014;63(8):2590-2599.
- 457 4. Pearson ER. Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. *Diabet Med.*458 2021;38(12):e14726.
- 5. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs.
- 460 *Diabetologia*. 2021;64(6):1201-1212.
- 461 6. Chedid V, Vijayvargiya P, Carlson P, et al. Allelic variant in the glucagon-like peptide 1
- 462 receptor gene associated with greater effect of liraglutide and exenatide on gastric
- 463 emptying: A pilot pharmacogenetics study. *Neurogastroenterol Motil.* 2018;30(7):e13313.
- 464 7. Mashayekhi M, Wilson JR, Jafarian-Kerman S, et al. Association of a glucagon-like peptide-
- 465 1 receptor gene variant with glucose response to a mixed meal. *Diabetes Obes Metab.*466 2021;23(1):281-286.
- 8. Bergman RN. Origins and History of the Minimal Model of Glucose Regulation. *Front Endocrinol (Lausanne)*. 2020;11:583016.
- 469 9. Muller TD, Bluher M, Tschop MH, DiMarchi RD. Anti-obesity drug discovery: advances and
 470 challenges. *Nat Rev Drug Discov*. 2022;21(3):201-223.

471	10. Mohammad S.	, Patel RT	, Bruno J	, Panhwar MS	, Wen J	, McGraw	TE. A natural	y occurring
-----	-----------------	------------	-----------	--------------	---------	----------	---------------	-------------

472 GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs

473 GIP control of adipose insulin sensitivity. *Mol Cell Biol.* 2014;34(19):3618-3629.

- 11. van der Velden WJC, Lindquist P, Madsen JS, et al. Molecular and in vivo phenotyping of
- 475 missense variants of the human glucagon receptor. *J Biol Chem.* 2022;298(2):101413.
- 476 12. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and
- 477 tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in
- healthy male subjects. *Diabetes Care*. 2002;25(8):1398-1404.
- 13. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity
- 480 and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol*
- 481 *Endocrinol Metab.* 2008;294(1):E15-26.
- 482 14. Quon MJ, Cochran C, Taylor SI, Eastman RC. Non-insulin-mediated glucose disappearance
- 483 in subjects with IDDM. Discordance between experimental results and minimal model
 484 analysis. *Diabetes.* 1994;43(7):890-896.
- I5. Fosam A, Yuditskaya S, Sarcone C, Grewal S, Fan H, Muniyappa R. Minimal Model-Derived
 Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black Americans. *Diabetes*
- 487 *Care*. 2021;44(11):2586-2588.
- 16. Becker RH, Stechl J, Msihid J, Kapitza C. Lixisenatide resensitizes the insulin-secretory
- response to intravenous glucose challenge in people with type 2 diabetes--a study in both
- 490 people with type 2 diabetes and healthy subjects. *Diabetes Obes Metab.* 2014;16(9):793491 800.
- 492 17. Beard JC, Bergman RN, Ward WK, Porte D, Jr. The insulin sensitivity index in nondiabetic
- 493 man. Correlation between clamp-derived and IVGTT-derived values. *Diabetes.*
- 494 1986;35(3):362-369.

495	18. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin
496	sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.
497	<i>Diabetes.</i> 1993;42(11):1663-1672.
498	19. Hager J, Hansen L, Vaisse C, et al. A missense mutation in the glucagon receptor gene is
499	associated with non-insulin-dependent diabetes mellitus. Nat Genet. 1995;9(3):299-304.
500	20. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS. Pharmacological characterization of
501	human incretin receptor missense variants. <i>J Pharmacol Exp Ther</i> . 2010;332(1):274-280.
502	21. Gabe MBN, van der Velden WJC, Gadgaard S, et al. Enhanced agonist residence time,
503	internalization rate and signalling of the GIP receptor variant [E354Q] facilitate receptor
504	desensitization and long-term impairment of the GIP system. Basic Clin Pharmacol Toxicol.
505	2020;126 Suppl 6:122-132.
506	22. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19
507	genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA.
508	2009;302(8):849-857.
509	23. Zhou K, Yee SW, Seiser EL, et al. Variation in the glucose transporter gene SLC2A2 is
510	associated with glycemic response to metformin. <i>Nat Genet</i> . 2016;48(9):1055-1059.
511	24. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in
512	type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet.
513	2019;394(10193):121-130.
514	25. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients
515	with Type 2 Diabetes. <i>N Engl J Med.</i> 2016;375(19):1834-1844.
516	26. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes
517	in Type 2 Diabetes. <i>N Engl J Med.</i> 2016;375(4):311-322.
518	27. Buse JB, Bain SC, Mann JFE, et al. Cardiovascular Risk Reduction With Liraglutide: An
519	Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care. 2020;43(7):1546-1552.

- 520 28. Taylor SI. GLP-1 receptor agonists: differentiation within the class. *Lancet Diabetes*
- 521 *Endocrinol.* 2018;6(2):83-85.
- 522 29. Aroda VR, Eckel RH. Reconsidering the role of glycaemic control in cardiovascular disease
- risk in type 2 diabetes: A 21st century assessment. *Diabetes Obes Metab.*
- 524 2022;24(12):2297-2308.
- 525 30. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW. Glucagon-like peptide 1 enhances
- 526 glucose tolerance both by stimulation of insulin release and by increasing insulin-
- 527 independent glucose disposal. *J Clin Invest.* 1994;93(5):2263-2266.
- 528 31. Meneilly GS, McIntosh CH, Pederson RA, et al. Effect of glucagon-like peptide 1 on non-
- 529 insulin-mediated glucose uptake in the elderly patient with diabetes. *Diabetes Care*.
- 530 2001;24(11):1951-1956.
- 32. Cobelli C, Bettini F, Caumo A, Quon MJ. Overestimation of minimal model glucose
- 532 effectiveness in presence of insulin response is due to undermodeling. *Am J Physiol.*
- 533 1998;275(6):E1031-1036.
- 33. Finegood DT, Tzur D. Reduced glucose effectiveness associated with reduced insulin
- release: an artifact of the minimal-model method. *Am J Physiol.* 1996;271(3 Pt 1):E485-495.
- 536 34. McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the
- 537 Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. *Endocr Rev.*538 2021;42(2):101-132.
- 539 35. Maselli D, Atieh J, Clark MM, et al. Effects of liraglutide on gastrointestinal functions and
- weight in obesity: A randomized clinical and pharmacogenomic trial. *Obesity (Silver Spring)*.
 2022;30(8):1608-1620.
- 542 36. Capozzi ME, DiMarchi RD, Tschop MH, Finan B, Campbell JE. Targeting the
- 543 Incretin/Glucagon System With Triagonists to Treat Diabetes. *Endocr Rev.* 2018;39(5):719-
- 544 738.

- 545 37. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in
 546 Patients with Type 2 Diabetes. *N Engl J Med.* 2021;385(6):503-515.
- 547 38. Bowker N, Hansford R, Burgess S, et al. Genetically Predicted Glucose-Dependent
- 548 Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by
- 549 Distinct Causal Variants in the GIPR Region. *Diabetes*. 2021;70(11):2706-2719.
- 39. Huang X, Orho M, Lehto M, Groop L. Lack of association between the Gly40Ser
- 551 polymorphism in the glucagon receptor gene and NIDDM in Finland. *Diabetologia*.
- 552 1995;38(10):1246-1248.

1	Supplementary Appendix
2	
3	Acute pharmacodynamic responses to exenatide:
4	Drug-induced increases in insulin secretion and glucose effectiveness
5	
6	Simeon I. Taylor MD, PhD ¹ May E. Montasser PhD ¹ Ashley H. Yuen MD ¹
7	Hubert Fan ² Zhinoosossadat Shahidzadeh Yazdi MD ¹ Hilary B. Whitlatch MD ¹
8	Braxton D. Mitchell PhD, MPH ¹ Alan R. Shuldiner MD ¹ Ranganath Muniyappa MD PhD ²
9	Elizabeth A. Streeten MD ¹ Amber L. Beitelshees PharmD, MPH ¹
10	
11	¹ Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of
12	Maryland School of Medicine, Baltimore, MD 21201, USA
13	² Diabetes, Endocrinology, and Obesity Branch, National institute of Diabetes and Digestive and
14	Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
15	
16	Correspondence
17	Simeon I. Taylor, MD, PhD, Department of Medicine, University of Maryland School of Medicine,
18	Baltimore, MD 21201, USA
19	Email: <u>staylor2@som.umaryland.edu</u>
20	
21	Funding information
22	American Diabetes Association (1-16-ICTS-112) and National Institute of Diabetes and
23	Digestive and Kidney Disease (R01DK130238, T32DK098107, and P30DK072488)

24 Table of Contents

25	1 Exclusion criteria	р. З
26	2 Frequently sampled intravenous glucose tolerance tests	p. 4
27	3 Clinical chemistry	р. 5
28	Table S1. Demographics and baseline characteristics of study population	р. 6
29	Table S2. Definition of parameters for statistical analyses	p. 7
30	Table S3. Interactions of genotype with pharmacodynamic responses to exenatide	p. 8
31	Figure S1. CONSORT diagram summarizing disposition of research participants	р. 9
32 33	Figure S2. Exenatide increases first phase insulin secretion and the rate of glucose disappearance in frequently sampled intravenous glucose tolerance tests	p. 11
34	Figure S3. Correlations between first and second phase insulin secretion	p. 12
35 36	Figure S4. Inter-individual variation in magnitude of responses to exenatide: first phase Insulin secretion and rate of glucose disappearance	р. 13
37		
38	4 References	p. 14

39 1 | Exclusion Criteria

- 40 Known allergy to exenatide
- History of diabetes, random glucose >200 mg/dL, or HbA1c > 6.5%
- 42 Significant cardiac, hepatic, pulmonary, or renal disease or other diseases that the
- 43 investigator judged would make interpretation of the results difficult or increase the risk of
- 44 participation
- 45 Seizure disorder
- Pregnant by self-report or known pregnancy within 3 months of the start of study
- Currently breast feeding or breast feeding within 3 months of the start of the study
- Estimated glomerular filtration rate <60 mL/min/1.73m²
- 49 Hematocrit <35%
- 50 Liver function tests greater than 2 times the upper limit of normal
- 51 Abnormal TSH
- 52 History of pancreatitis or pancreatic cancer. Personal or family history of medullary
- 53 carcinoma of the thyroid.

54 2 | Frequently sampled intravenous glucose tolerance tests

55	After an overnight fast, participants were transported to the Amish Research Clinic where
56	FSIGTs were performed (1Fo, 2). Two 20-gauge catheters were placed in antecubital veins
57	through which normal saline (60 mL/hr) was administered – one for intravenous administration
58	of D50W and one for obtaining blood samples. The infusion was stopped at times when blood
59	samples were withdrawn. To minimize dilution of blood, small amounts of blood were discarded
60	prior to obtaining blood samples. After placement of intravenous catheters, participants received
61	subcutaneous injections of either exenatide (5 μ g, sc) or saline (0.2 mL, sc). Fifteen minutes
62	after the subcutaneous injections, an intravenous bolus of glucose (0.3 g/kg) was infused over
63	two minutes. Thirty-one timed blood samples were obtained between -10- and +180-minutes
64	relative to the i.v. glucose infusion (1). Plasma samples were used to assay levels of glucose
65	and insulin.

67 3 | Clinical Chemistry

68	Screening blood samples were obtained by a research nurse during home visits and collected in
69	test tubes as appropriate for each assay: EDTA anticoagulant (purple top tube) for
70	measurement of hematocrit and HbA1c; heparin anticoagulant (green top tube) for
71	measurement of TSH; gray top tubes containing sodium fluoride and potassium oxalate for
72	measurement of fasting plasma glucose; red top tube for collecting serum samples. After
73	placing gray, purple, and green top tubes on ice, blood samples were transported to the clinical
74	laboratory at the Amish Research Clinic (maximum transport time, 2 hours). After centrifugation
75	(3300 rpm for 10 min), plasma/serum was sent on the same day to Quest Diagnostics for assay.
76	Blood samples for the frequently sampled intravenous glucose tolerance test were collected in
77	EDTA-containing purple top tubes for measurement of plasma insulin and in EDTA/oxalate-
78	containing gray top tubes for measurement of plasma glucose. Glucose was measured in
79	duplicate using an YSI glucose analyzer. Insulin was assayed in duplicate following the
80	manufacturer's directions using reagents in kits (#10-1113-01) purchased from Mercodia Inc.

81

Mean ± SEM (range)	Males	Females	Total
N (sample size)	33	21	54
Age (years)	46.0 ± 2.0	52.0 ± 2.1	48.3 ± 1.5
BMI (kg/m²)	27.3 ± 0.6	28.9 ± 0.8	27.9 ± 0.5
HbA1c (%)	5.51 ± 0.6	5.60 ± 0.7	5.54 ± 0.4
Serum creatinine (mg/dL)	0.88 ± 0.02	0.73 ± 0.02	0.82 ± 0.02
eGFR (mL/min/1.73 m ²)	101.2 ± 2.2	94.5 ± 3.4	98.6 ± 1.9
Hematocrit (%)	43.6 ± 0.4	39.0 ± 0.5	41.8 ± 0.4
Aspartate amino transferase (U/L)	18.5 ± 0.8	17.4 ± 0.9	18.1 ± 0.6
Alanine amino transferase (U/L)	21.0 ± 1.4	17.3 ± 1.1	19.6 ± 1.0

Table S1. Demographics and baseline characteristics of study population

85 Table S2. Definition of parameters for statistical analyses

Parameter	Definition
1 st phase insulin secretion	Area under the curve (AUC) for plasma insulin levels (0-10 min) calculated by trapezoidal rule
2 nd phase insulin secretion	Area under the curve for plasma insulin levels (10- 50 min) calculated by trapezoidal rule
Glucose disappearance rate	Slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: 1 st phase insulin secretion	Logarithm of AUC for 1 st phase insulin secretion when participant received exenatide – logarithm of AUC for 1 st phase insulin secretion when participant received saline.
Drug effect: 2 nd phase insulin secretion	Logarithm of AUC for 2 nd phase insulin secretion when participant received exenatide <i>minus</i> logarithm of AUC for 2 nd phase insulin secretion when participant received saline.
Drug effect: glucose disappearance rate	Glucose disappearance rate when participant received exenatide <i>minus</i> the glucose disappearance rate when participant received saline.
Log-transformed glucose disappearance rate	Logarithm of slope of the plot of the logarithm of glucose concentration versus time (25-50 min) calculated as the slope of the least square fit using Excel.
Drug effect: log-transformed glucose disappearance rate	Logarithm of glucose disappearance rate when participant received exenatide <i>minus</i> logarithm of the glucose disappearance rate when participant received saline.

87 **Table S3. Interactions of genotype with pharmacodynamic responses to exenatide.** Data

- 88 are expressed as means ± SEM. Insulin secretion was calculated as areas under the curve
- 89 (AUC) using the trapezoidal rule for times between 0-10 min (1st phase) and 10-50 min (2nd
- 90 phase). Three participants were excluded because their genotypes did not correspond to any of
- 91 the three groups. Two participants were homozygous for rs1801483 and heterozygous for
- rs1800437; one participant was homozygous for rs1800437 and heterozygous for rs1801483.
- 93 One participant who was homozygous for rs1801483 was excluded because of missing data. P-
- values were calculated using Student's t-test for paired values. To account for the 18 statistical
- comparisons in the Table, p<0.0025 was chosen as the criterion for statistical significance.

Treatment	Trait	WT	GCGR Homozygotes (rs1801483)	GIPR Homozygotes (rs1800437)
Placebo	Insulin AUC – 1 st phaseª	270 ± 40	244 ± 27 p=0.52	322 ± 55 p=0.46
Placebo	Insulin AUC – 2 nd phase ^a	626 ± 90	629 ± 74 p=0.98	626 ± 89 p=0.996
Placebo	Glucose disappearance ^b	489 ± 36	490 ± 54 p=0.99	626 ± 69 p=0.06
Exenatide	Insulin AUC – 1 st phase ^a	567 ± 90	423 ± 44 p=0.16	618 ± 155 p=0.77
Exenatide	Insulin AUC – 2 nd phase ^a	2718 ± 555	2132 ± 201 p=0.33	2244 ± 443 p=0.54
Exenatide	Glucose disappearance ^b	1011 ± 95	1052 ± 110 p=0.78	1302 ± 125 p=0.07
Drug Effect	Insulin AUC – 1 st phaseª	2.25 ± 0.31	2.00 ± 0.24 p=0.52	1.91 ± 0.27 p=0.44
Drug Effect	Insulin AUC – 2 nd phase ^a	4.49 ± 0.70	3.84 ± 0.36 p=0.41	3.71 ± 0.59 p=0.42
Drug Effect	Glucose disappearance ^b	2.19 ± 0.24	2.31 ± 0.27 p=0.73	3.34 ± 0.17 p=0.27
N	Sample size	19	19	13

96

^a Units of AUC for insulin secretion are μ U/ml \cdot min.

^a Units of glucose disappearance are min⁻¹.

99 Figure S1. CONSORT diagram summarizing disposition of research participants. Seventyeight individuals were enrolled in this clinical trial between June, 2016 - November, 2018. Sixty-100 101 two participants completed frequently sampled glucose tolerance tests. Twelve enrollees were 102 excluded for the following reasons (Fig. S1): low hematocrit (N=1), abnormal TSH levels (N=5), 103 abnormal liver function tests (N=1), family history of medullary carcinoma of the thyroid (N=1), primary hyperparathyroidism (N=1), low eGFR (N=1), poor venous access (N=1), and treatment 104 with warfarin (N=1). Thus, 66 individuals were judged to be eligible for the clinical trial. Three 105 106 individuals changed their minds and withdrew from the study after providing informed consent 107 but before undergoing an intravenous glucose tolerance test; technical challenges during one FSIGT led to withdrawal of an additional participant. The remaining 63 participants completed 108 the study. Ten individuals were excluded from the data base either because of missing data 109 110 (N=9) or outlier data (N=1). Thus, data from 53 individuals comprised the final database for 111 most of the analyses. Data from eight individuals' placebo FSIGTs could not be analyzed with the Minimal Model software because of issues related to data quality. Accordingly, Minimal 112 113 Model analysis of the FSIGT was based on data from 45 individuals. There were 27 reported adverse events of mild to moderate severity. Two participants reported feeling light-headed or 114 115 dizzy in the evening after leaving the Amish Research Clinic; these were classified as probably being related to the study. There were 11 events in which a participant's plasma glucose 116 (determined using a glucometer) was <70 mg/dL (52-63 mg/dL) at the end of an FSIGT. Three 117 participants reported symptoms (weakness, lightheadedness, or not feeling well) 60-90 minutes 118 119 after receiving intravenous glucose, at which time glucometer readings of 42 – 60 mg/dL were 120 obtained. Symptoms resolved quickly in all cases without intervention, and the FSIGT was not terminated. These were judged to be mild in severity and probably caused by the study. 121

122



125 Figure S2. Exenatide increases first phase insulin secretion and the rate of glucose

126 **disappearance in frequently sampled intravenous glucose tolerance tests.** Data are

127 presented as means of data for 53 research participants. The boxes encompass the 2nd and 3rd

- 128 quartiles; the "whiskers" correspond to the top and bottom quartiles (excluding outliers).
- 129 "Outliers" are depicted by the closed circles. Statistical significance (calculated using a paired t-
- test) is indicated on the graphs. Areas under the curve for 1st and 2nd phase insulin secretion are
- 131 expressed in the following units: $(\mu U/mL) \cdot min$.





133

135 Figure S3. Correlations between first and second phase insulin secretion. Intravenous

glucose triggers a biphasic response in the FSIGT: first phase insulin secretion (0-10 min) and second phase insulin secretion (10-50 min). Data are plotted as the logarithms of the areas under the curves for first and second phase insulin secretion; placebo studies are plotted in the left panel and exenatide studies in the right panel. Values for correlation coefficients (r) and pvalues are indicated in the figure. Areas under the curve for 1st and 2nd phase insulin secretion are expressed in the following units: (μ U/mL) · min.



- 145 Figure S4. Inter-individual variation in magnitude of responses to exenatide: first phase
- 146 **insulin secretion and rate of glucose disappearance.** Indices for effects of exenatide on first
- 147 phase insulin secretion^a and the rate of glucose disappearance^b are defined in Table 1.
- 148 Histograms depicting inter-individual variation are presented in the left panel for first phase
- insulin secretion and the right panel for the rate of glucose disappearance.
- 150 ^a Units of AUC for insulin secretion are μ U/ml \cdot min.
- ^a Units of glucose disappearance are min⁻¹.



155 **REFERENCES**

- 156
- 157 1. Muniyappa, R., Lee, S., Chen, H., and Quon, M. J. (2008) Current approaches for assessing
- insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage Am
- 159 J Physiol Endocrinol Metab **294**, E15-26 10.1152/ajpendo.00645.2007
- 160 2. Fosam, A., Yuditskaya, S., Sarcone, C., Grewal, S., Fan, H., and Muniyappa, R. (2021)
- 161 Minimal Model-Derived Insulin Sensitivity Index Underestimates Insulin Sensitivity in Black
- 162 Americans Diabetes Care **44**, 2586-2588 10.2337/dc21-0490